Abstract: The invention relates to lyophilized products and reconstituted emulsions for parenteral application, which comprise all the 13 essential vitamins (A, D, E, K1, C, B1, B2, B3, B5, B6, B7, B9, and B12) in a single container, as well as to methods for preparing them.

Abstract: Wound dressings, methods for forming the wound dressings, and methods for using the wound dressings are described. Wound dressings include a crosslinked hydrogel matrix and a plurality of porous absorbent microspheres encapsulated in the crosslinked matrix. The hydrogel matrix and the microspheres can include the same or different hydrogel polymers, e.g., alginates or the like. The wound dressings can be used in treating chronic wounds and burn wounds and can promote autolytic debridement.

Abstract: Apical wound debridement methods for wound healing provides a geometry of the wound area that enhances healing, either when using these methods alone or in combination with other wound healing grafts and medical devices. Further, the wound healing is used at a variety of locations where wounds are found, such as but not limited to the foot, ankle, leg, back, neck, arms, hands and face.

Abstract: Photodynamic therapy-based methods of treating diseases such as cancer and malaria are disclosed. These methods include administering 5-aminolevulinic acid (ALA), luminol and artemisinin (ART). ART and ALA administered in combination with luminol can kill malaria parasites without host toxicity. In some aspects, the methods further include administration of a luminol enhancer such as 4-iodophenol. The disclosed methods can also be used to remove potential malaria pathogens from the blood supply.

Abstract: In one of its aspects, the present invention provides a composition comprising: (i) a non-encapsulated iron salt, and (ii) a carrier comprising digestible edible oil that is a liquid at 20° C. This composition advantageously provides iron in a form that is easily administered to an infant or adult. When taken directly by mouth or added to food or infant formula, the composition has a desirably bland flavor and is easy to consume. Moreover, the high density of iron per unit volume of the composition results in a minimal volume of liquid to be administered. This makes the composition relatively innocuous and easy for infants to consume. Related aspects of the present invention are also described—e.g., uses, articles of manufacture and the like.

Abstract: A liquid food composition that can be conveniently ingested or given with a tube and contains reduced aggregates in the composition is provided. A liquid food composition that shows fluidity in the neutral region, but solidifies in the stomach environment is further provided. According to the production method of the present invention, generation of fine particles in the production process of a liquid food composition containing a divalent metal salt, a protein, and water-soluble dietary fibers is reduced. Therefore, emulsification stability of the composition is improved, clogging of aggregates in strainer disposed in the production line etc. are eliminated, and thus the composition can be efficiently produced.

Abstract: A blood coagulating device can include an absorbent body; and a hemostatic lysine composition associated with the body. The body can have a cylindrical or conical member having a first end having the hemostatic composition, the first end being configured for insertion into a nasal passageway. A method for coagulating blood can include providing a powdered hemostatic lysine composition; and applying the powdered hemostatic lysine composition to blood so as to cause the blood to coagulate and form a clot. The coagulation can occur in a nasal passageway away from a blood vessel. The method can include providing at least one absorbent member having the powdered hemostatic lysine composition; and applying the at least one absorbent member to the blood so that the powdered hemostatic lysine composition causes the blood to coagulate and clot.

Abstract: A bioactive agent in which the bioactive effectiveness of ferrous iron salt and/or ferric ferrous iron salt contained therein is stabilized, making long term preservation possible, so that the bioactive agent can be useful as an original solution for medical use, as a soil conditioner, or the like. An iron-magnesium mixture solution is provided in the invention, wherein the iron-magnesium mixture solution is produced by mixing an aqueous solution containing a ferrous iron salt and/or a ferric ferrous iron salt in a concentration of not less than 0.5 mol/L as iron in the ferrous iron salt and/or the ferric ferrous iron salt, and an aqueous solution containing a magnesium salt in a concentration of not less than 0.2 mol/L as magnesium in the magnesium salt.

Abstract: Methods for treating neoplasm, tumors and cancers, using one or more tumor treating drug carriers, haptens and anticancer drugs, alone or in combination with other antineoplastic agents or treatments, are provided. Also provided are compositions, and kits containing the composition for affecting the therapy.

Abstract: The invention provides nanodevices or products of manufacture for use as drug delivery vehicles. In one aspect, the invention provides nanodevices or products of manufacture having on-off release mechanisms, e.g., that are “switchable”, or “actuatable” (for example magnetically or ultrasonically switchable), for compounds contained within, e.g., for use as drug delivery nano-vehicles having on-off drug release mechanisms, and their therapeutic applications.

Abstract: The present invention relates to dietary and nutritional supplements comprising various vitamins, minerals and nutrients, including an omega-3 fatty acid of plant-based origin and a folate derivative.

Abstract: Provided are: a liquid for treatment of Citrus greening disease, which is capable of curing citrus trees with Citrus greening disease; and a treatment method using the liquid. The liquid for treatment of Citrus greening disease contains Fe ions and at least some of the Fe ions are present in the form of Fe2+ ions. This treatment liquid contains a predetermined amount of Fe ions and an acid. Citrus greening disease is able to be cured by spraying the treatment liquid onto leaves of citrus trees infected with Citrus greening disease or by pouring the treatment liquid on the roots of citrus trees infected with Citrus greening disease.

Abstract: Various agents and additives for cross-linking treatments are identified in disclosed studies. The characteristics of the various agents and additives may be advantageously employed in formulations applied in cross-linking treatments of the eye. In some embodiments, riboflavin is combined with Iron(II) to enhance the cross-linking activity generated by the riboflavin. In other embodiments, cross-linking treatments employ an Iron(II) solution in combination with a hydrogen peroxide pre-soak. In yet other embodiments, 2,3-butanedione is employed to increase the efficacy of corneal cross-linking with a photosensitizer, such as riboflavin. In further embodiments, folic acid is employed in combination with a photosensitizer, such as riboflavin, to enhance cross-linking activity. In yet further embodiments, 2,3-butanedione, folic acid, a quinoxaline, a quinoline, dibucaine, Methotrexate, menadione, or a derivative thereof is applied as a cross-linking agent.

Abstract: In one of its aspects, the present invention provides a composition comprising: (i) a non-encapsulated iron salt, and (ii) a carrier comprising digestible edible oil that is a liquid at 20° C. This composition advantageously provides iron in a form that is easily administered to an infant or adult. When taken directly by mouth or added to food or infant formula, the composition has a desirably bland flavor and is easy to consume. Moreover, the high density of iron per unit volume of the composition results in a minimal volume of liquid to be administered. This makes the composition relatively innocuous and easy for infants to consume. Related aspects of the present invention are also described—e.g., uses, articles of manufacture and the like.

Abstract: A composition comprising at least one penicillin, at least one iron source, and at least one oil, method of making, and method of use thereof are described. Although suitable for many forms and uses, the composition is, in some embodiments, suitable as a pharmaceutical composition, and, in some embodiments, as an antiviral composition capable of restoring T cell count and eradicating HIV virus from patients suffering from HIV/AIDS and other diseases including Tuberculosis.

Abstract: The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters.

Abstract: The present invention provides a composition comprising (i) a mixed metal compound containing at least one trivalent metal selected from iron (lll) and aluminium and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, (ii) xanthan gum (iii) at least one of (a) polyvinyl pyrrolidone (b) locust bean gum (c) methyl cellulose wherein the composition has been irradiated with ionising radiation in an amount of at least 4 kGy.

Abstract: Methods of preserving fresh produce with a produce preservative which extends the shelf life of fresh produce, particularly cut fresh produce, and preserves the texture, flavor, appearance, crispness, and color of the fresh produce, particularly the exposed surface of the fresh produce, are provided. The method comprises: providing a solution of produce preservative comprising: water; a preservative cation which is selected from the group consisting of a strontium ion, lithium ion, barium ion, aluminum ion, copper ion, ammonium ion, iron ion, manganese ion, potassium ion, or mixtures thereof; and ascorbate ions, or erythorbate ions; wherein the ascorbate ions or erythorbate ions and the preservative cation are present in an ion ratio of preferably from 0.2:1 to 8:1, more preferably 0.75:1 to 8:1, even more preferably from 1:1 to 4:1, yet more preferably 1.5:1 to 3:1; most preferably 1.1:1 to 2.5:1; and, applying said produce preservative to the produce.

Abstract: Shaped lyocell cellulose articles are provided for binding heavy metal ions and radioactive isotopes thereof. The shaped articles include one or more hexacyanoferrates that are incorporated in a cellulosic matrix and uniformly distributed therein. The shaped articles can be fibers, fibrids, fibrous nonwoven webs, granules, beads, self-supporting films, tubular films, filaments, sponges, foams or bristles. They are useful for water treatment and water decontamination, for metal beneficiation, for treatment of wound with wound dressings, for air and gas filtration and in protective apparel.

Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.

Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.

Abstract: Provided are: a liquid for treatment of Citrus greening disease, which is capable of curing citrus trees with Citrus greening disease; and a treatment method using the liquid. The liquid for treatment of Citrus greening disease contains Fe ions and at least some of the Fe ions are present in the form of Fe2+ ions. This treatment liquid contains a predetermined amount of Fe ions and an acid. Citrus greening disease is able to be cured by spraying the treatment liquid onto leaves of citrus trees infected with Citrus greening disease or by pouring the treatment liquid on the roots of citrus trees infected with Citrus greening disease.

Abstract: A composition and method for potentiating, sensitizing, and/or amplifying at least one HDAC inhibitor targeting at least one disease in a patient is provided. In one embodiment, the composition is administered to potentiate, sensitize and/or amplify an HDAC inhibitor targeting at least one cancer.

Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.

Abstract: Methods of normalizing iron levels, treating iron deficiency and disorders related thereto, such as anemia, as described. Pharmaceutical compositions effective for such treatments are also described.

Abstract: The present invention relates to compositions of an active pharmaceutical compound or nutritional ingredient with one or more buffering agents between a pH of 1.0 and 6.0, preferably 2.0 and 4.0. The buffering agents are constituted to maintain or reduce the pH of the duodenal fluid in the proximal, mid and distal duodenum. The present invention further relates to methods of improving the absorption of an iron compound or an active pharmaceutical compound within the small intestine. The present compositions and methods improve absorption or bioavailability of the administered compositions.

Abstract: Methods for treating neoplasm, tumors and cancers, using one or more tumor treating drug carriers, haptens and anticancer drugs, alone or in combination with other antineoplastic agents or treatments, are provided. Also provided are compositions, and kits containing the composition for affecting the therapy.

Abstract: In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders.

Abstract: The present invention is related to a formulation based on micronized natural calcite mineral consisting of: A. mineral part which is characterized: (i) by the particle size with diameter smaller than 5 ?m, where the distribution of particle size is such that minimum of 10% of particles are with diameter under 900 nm, with total surface of particles greater than 3.2 m2/g, and with total porous volume greater than 0.012 cm3/g, and by composition: (ii) CaCO3, MgCO3, FeCO3, MnCO3, ZnCO3 and SiO2 in mixtures where CaCO3 is presented in amount from 10% to 99% of mineral part; and B. adjuvant selected from the group consisting of: wetting agent, drift-control agent at application by spraying, humic acid salt, amino-acids salts, complex of plant micro-nutrients, vitamin, plant hormone, nitrogen fertilizer, potassium salt, borate salt, molybdate salt, plant extract, chlorophyll, yeast extract, or mixture of these substances; where A. and B. form an aqueous suspension wherein percentage of A. and B.

Abstract: Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.

Abstract: Ferrous sulfate and ferrous ammonium sulfate are known to kill moss and liverwort. They impart acidity in the lawn. Moss grows better in an acidic pH. The current invention proposes a formulation of ferrous sulfate or ferrous ammonium sulfate and zero valent iron with lime. Lime neutralizes the acidity produced by the ferrous salt and keeps the pH of the soil at 7 to 7.5. The formulation produces an immediate effect to eradicate moss and also provides a sustained effect over a long period. Another embodiment contains an addition of antimicrobial agents such as benzalkonium chloride, dichlorophen, and didecyldimethyl ammonium chloride to the ferrous sulfate-lime formulation.

Abstract: The object of the present invention is to stabilize bioactivation of iron salt. Said object is attained by adding a magnesium salt to said iron salt. Said iron salt stabilized by said magnesium salt is useful as medicine to treat incurable diseases such as diabetes and growth promoting agent of animals and plants.

Abstract: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronization preparation. The synchronization preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable theurapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvents. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocydic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocydic lactones include doramectin, ivermectin, abamectin and moxidectin.

Abstract: The present invention relates to an antifungal composition including at least two compounds selected from among the group consisting of cysteine, salicylic acid, iron(II) sulfate and fosetyl-aluminum, as well as to a method for treating a plant, infected or not infected by a pathogen. Specifically, the present invention relates to an antifungal composition for treating vineyards.

Abstract: To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. A therapeutic agent for a mitochondrial dysfunction brain disease, which comprises (A) ?-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof and (B) an iron compound in combination. R2R1NCH2COCH2CH2COR3 ??(1) wherein R1 and R2 each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group.

Abstract: Disclosed are microcapsules and processes of microencapsulation of water soluble or water dispersible compounds by reverse-phase microencapsulation and ways to combine them with other oil soluble or oil dispersible compounds in suitable formulations that yield tiny microcapsules and a very homogeneous distribution of particle size. Multiple combinations of these reverse-phase microcapsules are disclosed, including in combination with normal-phase microcapsules in order to create a Capsule Mixed Suspension (CX) where an outer oil phase or, alternatively, a water phase contains microcapsules of two types: those with a core of water and active ingredients dissolved or dispersed therein, and those with a core of oil and active ingredients dissolved or dispersed therein. Water Dispersible Granules (WDG) and Emulsion Concentrates (EC) and Suspension Concentrates (SC) combinations with the reverse phase microcapsules are also successfully performed.

Abstract: The invention disclosed in this document concerns controlling mealybugs.

Abstract: An antimicrobial and chemical deactivating composition for use in a liquid medium or for incorporation into a coating, structural plastic materials, thin microporous membranes, textiles and sponges. The composition includes macrosize or submicron particles of silver, platinum with silver and their salts with parabens, oxide, salicylate, acetate, citrate, benzoate and phosphate along with copper and zinc salts of the same.

Abstract: This invention relates to high surface area materials, such as nanoparticles, that are coated with metal ions. These modified nanoparticles have active sites that bind various gases and/or odorous compounds, thereby removing these compounds from a medium such as air or water. Metal ions are adsorbed onto the surface of the nanoparticle and bound strongly to the surface. By selection of the metal ion, specific gaseous compounds and/or odorous compounds can be targeted and removed efficiently and effectively from both aqueous phase and from the air. The modified nanoparticles are useful in numerous article of manufacture for industrial and consumer use.

Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.

Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

Abstract: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.

Abstract: The subject of the present invention is to provide a bioactivator which is useful as a medicine, growth promoting agent for plants and animals, and the like, wherein the bioactive effectiveness of a ferric salt is reinforced and stabilized. One or more kind of vitamin selected from a group consisting of vitamins C, E and K is (are) added to a ferric salt as an anti-oxidizing and bioactivity reinforcing agent, with a magnesium salt being further added as a stabilizer.

Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Abstract: The invention provides compositions and methods of treating various conditions, including neurological conditions, with pharmaceutical compositions including a sulfamate (e.g., topiramate) and magnesium.

Abstract: An antiviral agent is provided which can inactivate a wide range of viruses. Products that include such an antiviral agent are also provided. The present invention provides an antiviral agent that contains as an active ingredient a particle of at least one kind of iodide composed of iodine and an element shown in Period 4 to Period 6 and Group 8 to Group 15 of a periodic table or at least one kind of monovalent copper compound. The antiviral agent of the present invention can be designed at a higher degree of freedom in terms of its constituents as compared to conventional antiviral agents. In addition, the antiviral agent can readily exhibit and maintain its antiviral activity because it doesn't require any pretreatments or special washing processes.

Abstract: Multivitamin/Multimineral supplements are provided for supplementing iron and desirable nutrients in the diet of mammals. The supplements include an iron-amino acid chelate, a form of iron more bioavailable than traditional iron salts. The supplements may further include a pharmaceutically accepted salt form of iron as well as other nutritional vitamins and minerals. The supplements are useful for providing iron for pregnant and lactating females as well as for persons suffering from anemia.